

**GENOTYPING FOR POLYMOPRHISM OF *STK-15*, A LOW-PENETRANCE  
GENE IN COLORECTAL CANCER**

**NG CHEN SENG**

**PERPUSTAKAAN  
UNIVERSITI MALAYSIA SABAH**

**THIS DISSERTATION IS SUBMITTED TO FULFILL PARTIAL OF THE  
REQUIREMENT TO OBTAIN A DEGREE IN BACHELOR OF SCIENCE WITH  
HONOUR**

**BIOTECHNOLOGY PROGRAMME  
SCHOOL OF SCIENCE AND TECHNOLOGY  
UNIVERSITI MALAYSIA SABAH**

**2008**

## UNIVERSITI MALAYSIA SABAH

## BORANG PENGESAHAN STATUS TESIS@

JUDUL: GENOTYPING FOR POLYPOOPHISM OF STK-15  
A LOW-PENETRANCE GENE IN COLORECTAL CANCER

IJAZAH: SARJANA MUDA SAINS DENGAN KEPUJIAN  
BIOTEKNOLOGI

SAYA NG CHEN SENG  
(HURUF BESAR)

SESI PENGAJIAN: 2005 - 2008

mengaku membenarkan tesis (LPSM/Sarjana/Doktor Falsafah) ini disimpan di Perpustakaan Universiti Malaysia Sabah dengan syarat-syarat kegunaan seperti berikut:-

1. Tesis adalah hak milik Universiti Malaysia Sabah.
2. Perpustakaan Universiti Malaysia Sabah dibenarkan membuat salinan untuk tujuan pengajian sahaja.
3. Perpustakaan dibenarkan membuat salinan tesis ini sebagai bahan pertukaran antara institusi pengajian tinggi.
4. Sila tandakan (/)

SULIT

(Mengandungi maklumat yang berdarjah keselamatan atau Kepentingan Malaysia seperti yang termaktub di dalam AKTA RAHSIA RASMI 1972)

TERHAD

(Mengandungi maklumat TERHAD yang telah ditentukan oleh organisasi/badan di mana penyelidikan dijalankan)

TIDAK TERHAD

Disahkan Oleh

NURULAIN BINTI ISMAIL

LIBRARIAN

  
(TANDATANGAN PUSTAKAWAN)

Alamat Tetap: 82, JALAN PANDAN  
INDUSTRI 10, TAMAN PANDAN  
INDUSTRI 55100 KUALA LUMPUR

Nama Penyelia \_\_\_\_\_

Tarikh: 14/05/08

Tarikh: \_\_\_\_\_

CATATAN: \*Potong yang tidak berkenaan.

\*\*Jika tesis ini SULIT atau TERHAD, sila lampirkan surat daripada pihak berkuasa /organisasi berkenaan dengan menyatakan sekali sebab dan tempoh tesis ini perlu dikelaskan sebagai SULIT dan TERHAD.

@Tesis dimaksudkan sebagai tesis bagi Ijazah Doktor Falsafah dan Sarjana secara penyelidikan atau disertai bagi pengajian secara kerja kursus dan Laporan Projek Sarjana Muda (LPSM).

## DECLARATION

I declare that this dissertation is the result of my own independent work, except for the citations and quotations, in which the sources for each of them are acknowledged.

March 2008



NG CHEN SENG

HS2005-4752

**AUTHENTICATION**


AUTHENTICATED BY MEMBERS OF DISSERTATION COMMITTEE

**1. SUPERVISOR**


(Dr. Lee Ping Chin)

**2. EXAMINER**

(Dr. Wong Nyet Kui)

**3. DEAN**

(Associate Prof. Dr. Shariff A.K Omang)



## **ACKNOWLEDGEMENT**

This dissertation could only be completed with helping hands and guidance. Thus I am grateful and would like to seize on this golden opportunity to convey my highest appreciation to all of the people who have given me great supports either mentally or physically throughout the work in completing this dissertation. Firstly, I would like to thank my supervisor, Dr. Lee Ping Chin for her ongoing teaching, insight and support; for careful review of the manuscript, helpful suggestion and constructive criticisms, continuous encouragements and supervision on this dissertation. I would also like to thank to all the lecturers who have given me valuable educational knowledge. Besides, I wish to thank Glenda Wong for her valuable advices, teachings and guidance throughout the whole laboratory work for this dissertation. I would also like to express my sincere appreciation to my dearest course mates too for always being there to support me and to willingly share the knowledge and ideas to aid in troubleshooting.

## ABSTRACT

STK-15 protein or Aurora-A kinase play a vital role in regulating the cell division process. This preliminary study was conducted to investigate the association of polymorphisms Phe31Ile with colorectal cancer development. This non-synonymous coding region was believed to have important function in regulating the periodically proteasomal-ubiquitination degrading mechanism of STK-15 protein. To examine whether functional variation in *STK-15* may affect the susceptible risk, DNA samples from colorectal cancer patients ( $n = 11$ ) and healthy individual ( $n = 1$ ) were genotyped for Phe31Ile polymorphisms. Polymerase chain reaction-restriction fragment length polymorphism was used in this study. A restriction enzyme cutting site of *ApoI* is created when there is a polymorphism. Out of 11 samples, 9.09% were *Phe/Phe* genotype, 72.73% were *Phe/Ile* genotype and 18.18% were *Ile/Ile* genotype. The heterozygous might possibly have the highest risk in developing colorectal cancer. The samples were in Hardy-Weinberg-proportion ( $\chi^2 = 2.393, N=11$ ). Risk of association between polymorphisms of Phe31Ile in both alleles and colorectal cancer were investigated using OR, allele *Ile* was found to have high susceptibility risk (OR=1.20, 95% CI = 0.1-22.0) as compared to allele *Phe*. However, acting as a preliminary study, data obtained indicated that high occurrence rate of Phe31Ile polymorphism can be found in colorectal cancer individuals and it is worth to conduct a large scale and well designed study in the future.

## PENENTUAN GENOTIP POLIMOFISME GEN PENEMBUSAN RENDAH, *STK-15* DALAM KOLOREKTAL KANSER

### ABSTRAK

Protein STK-15 atau Aurora-A kinase memainkan peranan yang penting dalam mengawal proses pembahagian sel. Kajian primary ini telah dijalankan untuk mengkaji hubungan antara polimofisme pada bahagian Phe31Ile dengan penghidapan penyakit kolorektal kanser. Ketidak-synonymous pada bahagian ini dipercayai mempunyai peranan yang penting dalam mengawal proses mekanisma penghapusan protein STK-15 melalui ubiquitin yang berlaku pada masa yang tertentu. Demi mangkaji samada variasi yang berfungsi dalam protein STK-15 ini akan menjelaskan kadar penghidapan penyakit kolorektal kanser, sampel DNA daripada penghidap penyakit kolorektal kanser ( $n = 11$ ) dan seorang individu yang sihat ( $n = 1$ ) telah menjalani kajian penentuan genotip polimofisme pada bahagian Phe31Ile. Kaedah tindak balas rantai polimerase-pembatasan kepanjangan jujukan DNA polimofisme telah digunakan dalam kajian ini, pemotongan pada bahagian yang tertentu oleh *Apol* akan berlaku apabila mempunyai polimofisme. Daripada sebelas sampel yang dikumpul, 9.09% adalah *Phe/Phe* genotip, 72.73% adalah *Phe/Ile* genotip dan 18.18% adalah *Ile/Ile* genotip. Genotip heterozigot dipercayai mungkin mempunyai kadar risiko penghidapan penyakit kolorektal kanser yang paling tinggi. Kesemua sampel berada dalam keseimbangan Hardy-Weinberg ( $\chi^2 = 2.393$ ,  $N=11$ ). Hubungan antara kadar risiko penghidapan penyakit kolorektal kanser dan Phe31Ile polimofisme dalam kedua-dua alle telah dikaji menggunakan kaedah nisbah keganjilan (OR), alle *Ile* didapati mempunyai kadar risiko yang tertinggi dalam sehubung dengan penyakit kolorektal kanser ini (OR = 1.20, 95% CI = 0.1-22.0) berbanding dengan alle *Phe*. Walaubagaimanapun, sebagai kajian primary, data daripada kajian ini jelas menunjukkan bahawa terdapat kadar polimofisme Phe31Ile yang tinggi dalam pesakit kolorektal kanser, ini menunjukkan bahawa adalah berbaloi untuk menjalankan kajian ini dengan saiz sampel yang besar pada masa akan datang.

## TABLE OF CONTENTS

Page	
DECLARATION	ii
AUTHENTICATION	iii
ACKNOWLEDGEMENT	iv
ABSTRACT	v
ABSTRAK	vi
TABLE OF CONTENTS	vii
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF SYMBOLS, UNITS AND ABBREVIATION	xv
LIST OF APPENDIX	xvii
<b>CHAPTER 1 INTRODUCTION</b>	1
1.2 Objectives	3
<b>CHAPTER 2 LITERATURE REVIEW</b>	4
2.1 What is Colorectal Cancer	4
2.1.1 The Biology of Normal Colon	5
2.1.2 The Biology of Colorectal Cancer	5
2.2 The Genetics of Colorectal Cancer	5
2.2.1 Types of Mutations in CRC	7
2.2.2 Mutations in Oncogene	7
2.2.3 Mutation in Tumour Suppressor Gene	8
2.2.4 Mismatch Repair Gene	9
2.2.5 What is Polymorphism and SNP	10
2.2.6 Genetic Polymorphism Discovered Recently in CRC	10
2.2.7 Types of Polymorphism in STK-15	17
2.3 Other Factors that Influence the risk in CRC	18
2.3.1 Age	19
2.3.2 Gender	20
2.3.3 Race or Ethnicity	22

---

2.3.4	Dietary	23
2.3.5	Smoking and Alcohol Consumption	25
2.4	The Role of STK-15/Aurora-A in Cell-cycle Regulation	26
2.4.1	Centrosome separation and maturation	28
2.4.2	Spindle assembly	29
2.4.3	Mitotic Entry	31
2.4.4	Chromosome Alignment and cytokinesis process	33
2.5	High Penetrance and Low Penetrance Genes	34
2.5.1	Definition of High and Low Penetrance Genes	34
2.5.2	Examples of High and Low Penetrance Genes	34
2.6	Mechanism of Low Penetrance Genes in Cancer Development	39
2.7	Application of Single Nucleotide Polymorphism (SNP) Research	42
2.7.1	Disease Genetics	42
2.7.2	Pharmacogenetics	47
<b>CHAPTER 3</b>	<b>MATERIALS AND METHODS</b>	50
3.1	Colorectal Cancer Blood Samples	50
3.2	Setting up FlexiGene DNA Extraction Kit	51
3.2.1	Preparation of Reagents before Experiment	51
3.3	Optimum Condition Restored	52
3.4	Procedures in DNA Extraction	53
3.4.1	Pre-Treatment of Colonic Blood Samples with Buffer FG1	53
3.4.2	Centrifugation and Supernatant Discarded	53
3.4.3	Pre-Treatment with Buffer FG2/ QIAGEN® Protease solution	53
3.4.4	Centrifugation and Incubation	54
3.4.5	Pre-Treatment with 100% Isopropanol solution	54
3.4.6	Centrifugation and Supernatant Discarded	54
3.4.7	Pre-Treatment with 70% Ethanol solution	54
3.4.8	Centrifugation and Supernatant Discarded	54
3.4.9	Air-Dry and Pre-Treatment with Buffer FG3	55
3.4.10	The summary of protocols in DNA extraction	56

---

3.5	Description for DNA Separation in FlexiGene DNA Extraction Kit	58
3.5.1	Protease solution	58
3.5.4	Buffer FG1	58
3.5.5	Buffer FG2	59
3.5.6	Buffer FG3	59
3.6	PCR-Amplification of Purified DNA Samples	60
3.6.1	Preparation of PCR mixtures	60
3.6.2	Setting up the PCR schemes	61
3.6.3	Finalized Procedure	61
3.6.4	Description for reagents in PCR-amplification	61
3.6.5	The summary of protocols in PCR-amplification	62
3.7	Restriction Enzyme Digestion	63
3.7.1	Preparation of restriction enzyme mixture	63
3.7.2	The summary of protocols for restriction enzyme digestion	63
3.8	Agarose gel Electrophoresis	64
3.8.1	Preparing Reagents ..	64
3.8.2	Preparing the Gel-Loading Buffer	64
3.8.3	Preparing the Electrophoresis Buffer	64
3.8.4	Setting up gel-analysis apparatus	65
3.8.5	Casting the gel into the tank	65
3.8.6	Loading samples into the gel	66
3.8.7	Visualizing the results	66
3.8.8	Description for reagents in agarose gel electrophoresis	66
3.8.9	The summary of protocols for agarose gel electrophoresis	68
3.9	Statistical Analysis	69
3.9.1	Distribution of genotype	69
3.9.2	Allele and genotype frequency	69
3.9.3	Pearson's Chi-square analysis for Hardy-Weinberg proportion	70
3.9.4	Odds ratio with 95% of confidence interval	72
3.9.5	Fisher exact test	73
3.9.6	The summary of protocols in statistical analysis	74

---

<b>CHAPTER 4 RESULTS</b>	75
4.1 DNA extraction	75
4.2 PCR amplicons	77
4.3 Distribution of genotype among the colorectal cancer patients	79
4.4 Genotype frequency for both colorectal cancer patient and healthy sample	83
4.5 Pearson's Chi-square analysis for Hardy-Weinberg proportion	84
4.6 Odds ratio with 95% of confidence interval	86
4.6.1 Fisher exact test for significant association	88
4.7 <i>STK-15</i> Phe31Ile polymorphism and colorectal cancer susceptibility	89
<b>CHAPTER 5 DISCUSSION</b>	91
5.1 DNA extraction from blood samples using FlexiGene QIAGEN kit	91
5.2 Purity and concentration of extracted DNA	94
5.3 PCR-amplicon	95
5.4 Genotyping for polymorphism in <i>STK-15</i> gene	96
5.5 Association between <i>STK-15</i> Phe31Ile polymorphism and colorectal cancer susceptibility	99
5.5.1 Susceptibility risk	99
5.5.2 Mechanism in how polymorphism affects cancer development	100
<b>CHAPTER 6 CONCLUSION</b>	102
<b>LITERATURE RECITED</b>	104
<b>APPENDIX A</b>	139
<b>APPENDIX B</b>	140
<b>APPENDIX C</b>	144
<b>APPENDIX D</b>	146

## LIST OF TABLES

Table No.		Page
2.1	Types of genes' polymorphism being identified recently which have increased risk for CRC development	16
2.2	Seven types of polymorphisms identified in <i>STK-15</i> gene	17
2.3	Polymorphism in low-penetrance genes and their associated cancer	35
2.4	Polymorphism of low-penetrance genes and CRC susceptibility risk	37
2.5	SNP markers employed in recent studies of diseases association	43
3.1	Summary of reagents pre-treatment procedures in Qiagen kit	52
3.2	Reaction mixture for PCR amplification	60
3.3	PCR scheme for DNA amplification	61
4.1	Purity and concentration of DNA extracted from blood samples of colorectal cancer patients and healthy control	76
4.2	Distribution of genotypes among the colorectal cancer and control samples	82
4.3	Genotype frequency for both colorectal cancer cases and control	83
4.4	Pearson's Chi-square value for each genotype in cases samples	84
4.5	Pearson's Chi-square value for each genotype in control sample	85
4.6	Pearson's Chi-square analysis for Hardy-Weinberg proportion	85
4.7	P-value for significant difference from expected value	86
4.8	Total number for each allele in both cases and control sample	87
4.9	Allelic association test by OR with 95% CI	88
4.10	The summary for association of Phe31Ile <i>STK-15</i> gene with colorectal cancer	90

## LIST OF FIGURES

Figure No.	Page
2.1 The estimated number of CRC cases by age group in Malaysia year 2002	19
2.2 The estimated number of new CRC cases by sex in U.S. throughout the eight consecutive years (2000-2007)	20
2.3 The estimated number of death CRC cases by sex in U.S. throughout the eight consecutive years (2000-2007)	21
2.4 The estimated number of CRC cases by sex in Malaysia in year 2002	21
2.5 The estimated number of CRC cases by race in Malaysia in year 2002	23
2.6 How STK-15 cooperates with TPX2 in the process of spindle assembly regulation	31
2.7 Roles of low-penetrance genes in multistep of carcinogenesis development. Red arrow indicated the consequences of polymorphism in <i>STK-15</i> .	41
2.8 Outline of carcinogenesis in CRC and the potential points of biomarker. If <i>STK-15</i> being declared as a marker, the possible point will be as risk biomarker (red arrow)	46
4.1 The PCR amplification product was subjected to analysis on 2.0% of agarose gel electrophoresis and the expected size of 165 bp were obtained.	78
4.2 Analysis of <i>STK15</i> polymorphisms. Results indicated that S3 was homozygous wild type ( <i>Phe/Phe</i> , <i>+/+</i> ), S7 and S9 were homozygous variant ( <i>Ile/Ile</i> , <i>-/-</i> ), S11, S15 and S16 were heterozygous ( <i>Phe/Ile</i> , <i>+/-</i> ). S6, S20, S22, S24 and S27 were unable to interpret accurately. Result was reconfirmed in Figure 4.3. Size 12 bp was unable to observe as the size were extremely small.	80
4.3 Reconfirmation study was conducted under similar condition for S6, S20, S22, S24 and S27 with a higher concentration of DNA. Analysis showed that all the five were heterozygous ( <i>Phe/Ile</i> , <i>+/-</i> ). Extra lane for control was added in this study and the result indicated that it was	

	heterozygous as well.	81
4.4	Bar chart showing the percentage of the genotype among the collected CRC samples, 72.73% was <i>Phe/Ile</i> genotypes, 18.18% was <i>Ile/Ile</i> genotypes and only 9.09% was <i>Phe/Phe</i> genotypes.	82
5.1	Restriction mapping on how homozygote, homozygote variant and heterozygote producing different size of bands when exposed to <i>ApoI</i> . <i>Phe/Phe</i> displayed two possible cutting site (A, B) where each does produce two bands—153 bp & 12 bp, <i>Ile/Ile</i> displayed six possible cutting side (C, D, E, F, G, H), each of it produced three bands—89 bp, 64 bp & 12 bp while <i>Phe/Ile</i> displayed four possible combinations (A & F, A & G, B & D, B & E) at where each of it producing four bands—153 bp, 89 bp, 64 bp & 12 bp.	97
5.2	Amino acid sequence for <i>STK-15</i> gene (Accession ID: NP_003591), With the total number of 404 amino acids, possess the amino acid Phenylalanine (F, red mark) at position 31 if without polymorphism. However, with the presence of polymorphism, this amino acid will change to amino acid of Isoleucine (I).  (Source: <a href="http://www.ncbi.nlm.nih.gov/snp">http://www.ncbi.nlm.nih.gov/snp</a> , surfed date: 08 May 2008)	98
5.3	Part of the nucleotide sequence for <i>STK-15</i> gene where there was a changed of single nucleotide polymorphism (T, red mark) to A, creating another restriction site for enzyme <i>ApoI</i> . The same restriction site ( <b>AATT</b> ) within the same exon was displayed as well (bold and underlined).  (Source: <a href="http://snp500cancer.nci.nih.gov/">http://snp500cancer.nci.nih.gov/</a> , surfed date: 08 May 2008)	98

## LIST OF SYMBOLS, UNITS AND ABBREVIATION

w/v	weight over volume
v/v	volume over volume
%	percent
s	second
ml	mililiter
$\mu$ l	microliter
$^{\circ}$ C	degree Celcius
r.p.m	rotation per minute
M	Molar
mM	millimolar
$\mu$ M	microMolar
mm	millimeter
mg/ml	milligram per milliliter
min	minute
V	volt
DNA	deoxyribonucleic acid
PBS	phosphate-buffer-saline
RT	room temperature
TE	Tris-EDTA
PCR	polymerase chain reaction
dNTP	deoxynucleotides-triphosphate
NaOH	sodium hydroxide
HCl	hydrochloride
BSA	bovine serum albumin
UV	ultraviolet
dH <sub>2</sub> O	distilled water
BTAK	Breast Tumour Amplified Kinase
STK-15	serine/threonine kinases-15
SNP	single nucleotide polymorphism
MSI	microsatellite instability

MMR	mismatch repair
CRC	colorectal cancer
GST	glutathione S-Transferase
GSTO	gluththione S-Transferase Omega
XRCC3	X-ray cross complementing-3
Thr	threonine
Met	methionine
PAI-1	plasminogen activator inhibitor-1
MTHFR	methylenetetrahydrofolate reductase
NAT-2	<i>N</i> -acetyltransferase-2
VDR	vitamin D receptor
COX-2	cyclooxygenase-2
TS	thymidylate synthase
dTMP	deoxythymidine monophosphate
dUMP	deoxyuidine monophosphate
5-FU	5-fluorouracil
PP1	protein phosphate 1
Cdk	cyclin-dependent kinase
CIP	Cdks inhibitory protein
INCENP	inner centromere protein
ALDH	alcohol dehydrogenase
CYP	Cytochrome P450
XME	xenobiotic metabolizing enzymes
XPD	xeroderma pigmentosum group D
WRN	Werner syndrome gene
UGT	UDP-glucuronosyltransferase
ADR	adverse drug effect
FGD	familial glucocorticoid deficiency
MRAP	melanocortin 2 receptor accessory protein
OA	osteoarthritis
AKR1B1	aldose reductase
SULT1A1	sulfotransferase A1
G	glycine

---

Q	glutamine
D	aspartic acid
R	arginine
Y	tyrosine
A	alanine
K	lysine
T	threonine
C	cysteine
S	serine
F	phenylalanine
I	isoleucine
FAP	Familial Adenomatous Polyposis
HNPPCC	Hereditary Nonpolyposis Colorectal Cancer
OR	Odds ratio
CI	Confidence interval
<i>df</i>	Degrees of freedom

**LIST OF APPENDIX**

Appendix No.	Page
A. Full sequence length for STK-15 gene ( <i>Homo sapiens</i> )	139
B. Working steps for statistical analysis	140
B1. Calculation for allele and genotype frequency using Hardy-Weinberg Equation.	140
B2. Calculation for Hardy-Weinberg proportion.	141
B3. Calculation for odds ratio (OR) and 95% of confidence interval (CI)	142
B4. Fisher Exact test for statistically significant of allelic association test.	143
C. Chi-Square ( $\chi^2$ ) Distribution Table	144
D. Chi-Square ( $\chi^2$ ) Distribution Table for <i>p</i> -value	146

## **CHAPTER 1**

### **INTRODUCTION**

#### **1.1 Introduction**

STK-15, which is also known as Aurora-A, Aurora-2 or Breast Tumour Amplified Kinase (abbreviated as BTAK for its first discoveries in breast tumour), can be clarified also as STK-6 for its homologues found in *Drosophila melanogaster* or AIR-1 in *C. elegans*. STK-15 belongs to one of the family of mitotic kinases, which is a type of serine/threonine kinases, primarily known as Aurora kinases/Ipl1-related kinases. (Dai *et al.*, 2004; Marumoto *et al.*, 2005). Research and studies have been conducted to show that the Aurora kinases play vital role in regulating the progression of cell cycle especially in controlling some of the major events like centrosome maturation, chromosome condensation, centrosome separation, degradation of nuclear-envelope, the congregation of bipolar-spindle, chromosome segregation and the process of cytokinesis (Zhou *et al.*, 1998; Gritsko *et al.*, 2003; Li *et al.*, 2003; Marumoto *et al.*, 2005).

Studies have shown that human comprises three classes of Aurora kinases—Aurora-A, Aurora-B and Aurora C. Research had also indicated that all the three classes of Aurora kinases are involved in the development of different types of cancer. However, in this research, only the class STK-15/Aurora-A will be further elucidated. STK-15/Aurora-A is being found to express mostly in all the types of cells and specifically, the protein STK-15/Aurora-A is being coded by the gene STK-15 is found to be located on the chromosome 20q13.2.

As for this dissertation, we are going to examine the effect of the mechanism of polymorphisms on this putative oncogene STK-15/Aurora-A specifically for colorectal cancer patients. Research has shown that STK-15/Aurora-A is being overexpressed and amplified during the progression of cell-cycle and leads to the development of cancer. Many types of cancer are involved such as breast cancer, colorectal cancer, pancreatic cancer (Li *et al.*, 2003), prostate cancer, ovarian cancer, neuroblastoma cancer, cervical cancer, lung cancer, renal cancer, gastric cancer and melanoma cell lines. (Bischoff *et al.*, 1998; Zhou *et al.*, 1998).

However, polymorphisms of STK15/Aurora-A is not the sole cause that leads to the onset of colorectal cancer since it also possesses three other major reasons such as the mutations in tumour suppressor genes, oncogenes and DNA mismatch repair genes. Since both polymorphisms and the presence of low penetrance genes have been the useful biomarkers for the signal of cancer development, therefore, both searching for polymorphisms and low penetrance genes have been utilized as one of the effective methodology in knowing the potential of a patient to develop cancer at the present days.

Despite there have been numerous volumes of literatures regarding the colorectal cancer at the present days, patients developing this type of cancer had never been reduced. In year 2006, there were more than 55,000 cases of death solely belongs to colorectal patients in United States (Hung *et al.*, 2006) and as for Malaysia, colorectal cancer had become the leading type of diseases. This entire phenomenon conveys a message for us that there is still a compelling need to search for new therapies and detection methods for this cancer.

## 1.2 Objectives

The Main Objectives of this dissertation are:

- (i) To extract DNA from biopsy samples of colorectal cancer.
- (ii) To test the presence of Phe31Ile single nucleotide polymorphism (SNP) in putative oncogene *STK15/Aurora-A*.
- (iii) To investigate to what extent the single nucleotide polymorphism of Phe31Ile in STK-15 associated with susceptibility risk in developing colorectal cancer.

## **CHAPTER 2**

### **LITERATURE REVIEW**

#### **2.1 What is Colorectal Cancer?**

Colon Cancer or more accurately being known as colorectal cancer is being defined as clusters of malignant (cancerous) cells form and develop surrounding the tissues of the colon organ within our stomach (Feldman *et al.*, 2002; Warrell *et al.*, 2003).

#### **2.1.1 The Biology of Normal Colon**

As in a normal condition of the organ colon, it comprises a single layer of column-like shape of epithelial cells which are being organized into invaginations, primary known as crypts. When we observed carefully, we will be able to discover that those crypts can actually being subdivided into two distinct zones. The first zone belongs to a proliferative compartment, which comprises cells at the bottom portion of the crypts. While for the second zone, it comprises cells in the upper portion of the crypts and this zone is known as differentiated zone (Warrell *et al.*, 2003).

## 2.1.2 The Biology of Colorectal Cancer

Colorectal cancer can only be onset when a structure known as polyps started to develop. This polyps structure basically can be defined as a growth arising from the intestine itself, protruding into the lumen of the colon. Sometimes also being known as lesions and these polyps can be seen through naked eyes (visible).

This polyps basically can be arisen from different parts of the colon, sometimes it might arise from subepithelial tissues and sometimes it might arise from the intestinal epithelium. Polyps arising from the latter can be the matter of life and death since it can be the precursor for the development of colorectal adenocarcinomas. When we come across the disease cancer, we can classify its severity based on its histology. As for the disease of cancer, term “benign” is used for no life-threatening condition and the term “malignant” for harmful or likely to cause death.

Polyps have the same situation at where whether it is benign or malignant, it is thoroughly based on its histology. As for colorectal cancer, we have the term “non-neoplastic” for benign or very unlikely to transform into malignancies and “neoplastic” for malignant or very likely to develop malignancies (Kim and Lance, 1997). Under the histology studies, colorectal cancer will be declared officially when a neoplastic stage has achieved. However, a recent study on hyperplastic polyps, which is the enlargement or unusual growth within the colon, which is normally caused by an abnormal increased of cells do show an increased risk in developing colorectal cancer (Rashid *et al.*, 2000).

As for neoplastic in colorectal cancer is known as adenomatous polyps. Patients who develop these polyps are very likely or have higher percentage to develop malignancies. They can be further classifies into low-, medium- and high-grade. As in high-grade stage, the polyps normally can reach the size of about 1 cm and are villous (hairy) (Appel *et al.*, 1977). Study has also shown that in order to develop colorectal cancer from small polyps, normally it has to take eleven years to bring it on (Stryker *et al.*, 1987).

Studies have also proven that the locations of those polyps are also affecting the development of colorectal cancer. According to the studies, polyps locating at the left side of the colon will be more susceptible to develop colorectal cancer (Vatn M. H and Stalsberg H., 1982; Williams *et al.*, 1982; Coode *et al.*, 1985; Johannsen *et al.*, 1989).

## **2.2 The Genetics of Colorectal Cancer**

One of the causes for colorectal cancer (CRC), in fact we should say that this is the major cause contributing to the development of CRC, will be the mutations of certain genes. CRC arise from mutations in multiple cancer causing-genes in colonic epithelial cells, at where it had been mentioned by Balmain and his colleagues that most cancer is a polygenic disorder (Balmain *et al.*, 2003).

## LITERATURE RECITED

- Adams, R.R., Carmena, M. & Earnshaw, W.C. 2001. Chromosomal passengers and the (aurora) ABCs of mitosis. *Trends in Cell Biology* 11, pg. 49-54.
- Ahmed, K.M., Shitara, Y., Takenoshita, S., Kuwano, H., Saruhashi S. & Shinozawa, T. 2002. Association of an intronic polymorphism in the midkine (MK) gene with human sporadic colorectal cancer. *Cancer Letters* 180, pg. 159-163.
- Anand, S., Penrhyn-Lowe, S. & Venkitaraman, A.R. 2003. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. *Cancer Cell* 3, pg. 51-62.
- Apper, M.F., Spjut, H.J. & Estrada, R.G. 1977. The significance of villous component in colonic polyps. *American Journal of Surgery* 134, pg. 770-771.
- Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. & Struhl, K. 2005. *Short Protocols In Molecular Biology, 5<sup>th</sup> Edition, Volume 1*. John Wiley & Sons. Inc Publishers.
- Balmain A., Gray J. & Ponder B. 2003. The Genetics and Genomics of Cancer. *Nature Genetics* 22, pg. 238-243.
- Baker, S.M., Bronner, C.E., Zhang, L., Plug, A.W., Robatzek, M., Warren, G., Elliott, E.A., Yu, J., Ashley, T., Arnheim, N., Flavelle, R.A. & Liskay, M. 1995. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. *Cell* 82, pg. 309-319.
- Baron, J.A., Gerhardsson de Verdier, M. & Ekbom, A. 1994. Coffee, tea, tobacco, and cancer of the large bowel. *Cancer Epidemiology, Biomarkers and Prevention* 3, pg. 565-570.

- Berdnik, D. & Knoblich, J.A. 2002. *Drosophila* Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. *Current Biology* 12, pg. 640-647.
- Bethesda. 1997. SEER Cancer Statistic Review, 1972-1996. *Surveillance Epidemiology and End Results*.
- Bischoff, J.R., Anderson, L., Zhu, Y., Mossie, K., Ng, L., Souza B., Schryver B., Flanagan, P., Clairvoyant, F., Ginther, C., Chan, C.S., Novotny, M., Slamon, D.J. & Plowman, G.D. 1998. A homologue of *Drosophila* aurora kinase is oncogenic and amplified in human colorectal cancers. *Journal of European Molecular Biology* 17, pg. 3052-65.
- Bischoff, J.R. & Plowman, G.D. 1999. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. *Trends in Cell Biology* 9, pg. 454-459.
- Bishop, J.M. 1981. Oncogenes. *Scientific American* 140, pg. 69.
- Blagden, S.P. & Glover, D.M. 2003. Polar expeditions—provisioning the centrosome for mitosis. *Nature of Cell Biology* 5, pg. 505-511.
- Blount, B.C., Mack, M.M., Wehr, C.M., MacGregor, J.T., Hiatt, R.A., Gene Wang, Wickramasinghe, S.N., Everson, R.B. & Ames, B.N. 1997. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. *Proceedings of the National Academy of Sciences, USA* 94, pg. 3290-3295.
- Brennan, P. 2002. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? *Carcinogenesis* 23, pg. 381-387.

Brittle, A.L. & Ohkura, H. 2005. Centrosome Maturation: Aurora Lights the Way to the Poles. *Current Biology* 15 (21), pg. 880-882.

Brockton, N., Little, J., Sharp, L. & Cotton S.C. 2000. N-Acetyltransferase Polymorphisms and Colorectal Cancer: A Huge Review. *American Journal of Epidemiology* 151 (9), pg. 846-861.

Brookes, A.J. 1999. The essence of SNPs. *Gene* 234, pg. 177-186.

Bossetta, P. & Hashibe, M. 2006. Alcohol and cancer. *Lancet Oncology* 7, pg. 149-156.

Boland, C.R., Thibodeau, S.N., Hamilton, S.R., Sidransky, D., Eshleman, J.R., Burt, R.W., Meltzer, S.J., Rodriguez-Bigas, M.A., Fodde, R., Ranzani G.N. & Srivastava, S. 1998. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Research* 58, pg. 5248-5257.

Boyd, J. 1996. BRCA2 as a Low-Penetrance Cancer Gene. *Journal of the National Cancer Institute* 88 (19), pg. 1408-1409.

Calvert, P.M. & Frucht, H. 2002. The Genetics of Colorectal Cancer. *Annals of Internal Medicine (Review)* 137, pg. 603-612.

Caporaso, N.E. 2002. Why Have We Failed to Find the Low Penetrance Genetic Constituents of Common Cancers? *Cancer Epidemiology, Biomarkers & Prevention* 11, pg. 1544-1549.

Cartwright, C. 1998. Intestinal cell growth control: role of Src tyrosine kinases. *Gastroenterology* 114, pg. 1335-1338.

- Chadwick, R.B., Jiang, G.L., Bennington, G.A., Yuan, B., Johnson, C.K., Stevens, M.W., Niemann, T.H., Peltomaki, P., Huang, S. & Albert de la Chapelle. 1999. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. *Proceedings of the National Academy of Sciences, USA* 97(6), pg. 2662-2667.
- Chen, J., Giovannucci, E., Hankinson, S.E., Ma, J., Willett, W.C., Spiegelman, D., Kelsey, K.T. & Hunter, D.J. 1998. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. *Carcinogenesis* 19 (12), pg. 2129-2132.
- Choi, S.W., Kim, Y.I., Weitzel, J.N. & Mason, J.B. 1998. Folate depletion impairs DNA excision repair in the colon of the rat. *Gut* 43, pg. 93-99.
- Choi, S.W. & Mason, J.B. 1998. Folate and colorectal carcinogenesis: is DNA repair the missing link? *American Journal of Gastroenterology* 93, pg. 2013-2016.
- Choi, S.W. & Mason, J.B. 2000. Folate and carcinogenesis: an integrated scheme. *Journal of Nutrition* 130, pg. 129-132.
- Chung, D.C. & Rutsgi, A.K. 1995. DNA mismatch repair and cancer. *Gastroenterology* 109, pg. 1685-1699.
- Coode, P.E., Chan, K.W. & Chan, Y.T. 1985. Polyps and diverticula of the large intestine: a necropsy survey in Hong Kong. *GUT* 26, pg. 1045-1048.
- Cravo, M.L., Albuquerque, C.M., Salazar de Sousa, L., Gloria, L.M., Chaves, P., Pereira, A.D., Leitao, C.N., Quina, M.G. & Mira, F.C. 1998. Microsatellite instability in non-neoplastic mucosa of patients with ulcerative colitis: effect of folate supplementation. *American Journal of Gastroenterology* 93, pg. 2060-2064.

- Cravo, M.L., Fidalgo, P., Pereira, A.D., Oliveira, A.G., Chaves, P., Selhub, J., Mason, J.B., Mira, F.C. & Leitao, C.N. 1994. DNA methylation as an intermediate biomarker in colorectal cancer; modulation by folic acid supplementation. *European Journal of Cancer Prevention* 3, pg. 473-479.
- Cravo, M.L., Mason, J.B., Dayal, Y., Hutchinson, M., Smith, D., Selhub, J. & Rosenberg, I.H. 1992. Folate deficiency enhances the development of colonic neoplasia in dimethylhydrazine-treated rats. *Cancer Research* 52, pg. 5002-5006.
- Crow, J.F. 1999. Hardy, Weinberg and language impediments. *Genetics* 152, pg. 821-825.
- Cox, D.G., Pontes, C., Guino, E., Moreno, V., Canzian, F., Osorio, A. & Navarro, M. 2004. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. *British Journal of Cancer* 91 (2), pg. 339-343.
- Dai, Q., Cai, Q.Y., Shu, X.O., Edward-Toland, A., Wen, W.Q., Balmain, A., Gao, Y.T. & Wei, Z. 2004. Synergistic Effects of STK15 Gene Polymorphisms and Endogenous Estrogen Exposure in the Risk of Breast Cancer. *Cancer Epidemiology, Biomarkers & Prevention* 13, pg. 2065-70.
- De Mars, R. 1969. Mutation of genes with the exposure risk in colon cancer. *Science* 164 (3885), pg. 1303-1305.
- DiCioccio, R.A., Song, H., Waterfall, C., Kimura, M.T., Nagase, H., McGuire, V., Hogdall, E., Shah, M.N., Luben, R.N., Easton, D.F., Jacobs, I.J., Ponder, B.A.J., Whittermore, A.S., Gayther, S.A., Pharoah, P.D.P. & Krujer-Kjaer, S. 2004. STK15 Polymorphisms and Association with Risk of Invasive Ovarian Cancer. *Cancer Epidemiology, Biomarkers and Prevention* 13, pg. 1589-94.

- Doll, R., Forman, D., La Vecchia, C. & Woutersen, R. 1999. *Alcoholic beverages and cancers of the digestive tract and larynx*. In Macdonald I (ed.) *Health Issues Related to Alcohol Consumption*, 2nd edn. pg. 351–393. Bodmin, Cornwall: MPG Books Limited.
- Doxsey, S. 1998. The centrosome—a tiny organelle with big potential. *Nature Genetics* 20, pg. 104-106.
- Ducat, D. & Zheng, Y. 2004. Aurora kinases in spindle assembly and chromosome segregation. *Experimental Cell Research* 301, pg. 60-67.
- Duesberg P.H. 1983. Retroviral transforming genes in normal cells? *Nature Genetics* 6, pg. 219-226.
- Dutertre, S., Cazales, M., Quaranta, M., Froment, C., Trabut, V., Dozier, C., Mirey, G., Bouché, J.P., Theis-Febvre, N., Schmitt, E., Monsarrat, B., Prigent, C. & Ducommun, B. 2004. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. *Journal of Cell Science* 117 (12), pg. 2523-2531.
- Egan, K.M., Newcomb, P.A., Ambrosone, C.B., Trentham-Dietz, A., Titus-Ernstoff, L., Hampton, J.M., Kimura, M.T. & Nagase, H. 2004. STK15 polymorphism and breast cancer risk in a population-based study. *Carcinogenesis* 25 (11), pg. 2149-2153.
- Eisman, J.A., Barkla, D.H. & Tutton, P.J.M. 1987. Suppression of in vivo growth of human cancer solid tumor xenographs by 1, 25-dihydroxyvitamin D3. *Cancer Research* 47, pg. 227-231.
- Evan, G.I. & Voudsen, K.H. 2001. Proliferation, cell cycle and apoptosis in cancer. *Nature* 411, pg. 342-348.

Ewart-Toland, A., Briassouli, P., P de Koning, J., Mao, J.H., Yuan, J., Chan F., MacCarthy-Morrogh, L., Ponder B.A.J., Nagase H., Burn, J., Ball, S., Almeida, M., Linardopoulos, S. & Balmain, A. 2003. Identification of *Stk6/STK15* as a candidate low penetrance tumor susceptibility gene in mouse and human. *Nature Genetics* 34, pg. 403-412.

Ewart-Toland, A., Dai, Q., Gao, Y.T., Nagase, H., Dunlop, M.G., Farrington, S.M., Barnetson, R.A., AntonCulver, H., Peel, D., Ziogas, A., Lin, D., Miao, X., Sun, T., Ostrander, E.A., Stanford, J.L., Langlois, M., Chan, J.M., Yuan, J., Harris, C.C., Bowman E.D., Clayman, G.L., Lippman, S.M., Lee, J.J., Zheng, W. & Balmain, A. 2005. Aurora-A/STK-15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. *Carcinogenesis* 26 (8), pg. 1368-1373.

Eyers, P.A., Erikson, E., Chen, L.G. & Maller, J.L. 2003. A novel mechanism for activation of the protein kinase aurora a. *Current Biology* 13, pg. 691-697.

Farruggio, D.C., Townsley, F.M. & Ruderman, J.V. 1999. Cdc20 associates with the kinase aurora2/Aik. *Cell Biology* 96, pg. 7306-11.

Fearon, E.R. & Vogelstein, B. 1990. A genetic model for colorectal tumorigenesis. *Cell* 61, pg. 759-767.

Feinberg, A.P., Gehrke, C.W., Kuo K.C. & Ehrlich M. 1988. Reduced genomic 5-methylcytosine content in human colonic neoplasia. *Cancer Research* 48, pg. 1159-1161.

Feldman, M., Friedman, L.S. & Sleisenger, M.H. 2002. *Gastrointestinal and Liver Disease, Pathophysiology/Diagnosis/Management*, vol. 2, 7<sup>th</sup> Edition. Saunders Publishers, an Imprinted of Elsevier Science Ltd, pg. 1643-1654.

- Franceschi, S. & La Vecchia, C. 1994. Alcohol and the risk of cancers of the stomach and colon-rectum. *Digestive Disease (Basel, Switzerland)* **12**, pg. 276-89.
- Fraizer, G.C., Diaz, M.F., Lee, I-L., Grossman, H.B. & Sen, S. 2004. Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. *International Journal of Oncology* **25**, pg. 1631-1639.
- Friend, S.H. 1996. Breast cancer susceptibility testing: realities in the post-genomic era. *Nature Genetics* **13**, pg. 16-17.
- Feinberg, A.P & Vogelstein, B. 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. *Nature* **301**, pg. 89-92.
- Fenech, M. & Rinaldi, J. 1994. The relationship between micronuclei in human lymphocytes and plasma levels of vitamin C, vitamin E, vitamin B12 and folic acid. *Carcinogenesis* **15**, pg. 1405-1411.
- Fisher, R.A. 1922. On the interpretation of  $\chi^2$  from contingency tables, and the calculation of P. *Journal of Royal Statistical Society* **85** (1), pg. 87-94.
- Flood, D., Weiss, N., Cook, L., Emerson, J.C., Schwartz, S.M. & Potter, J.D. 2000. Colorectal Cancer incidence in Asian migrants in the United States and their descendants. *Cancer Causes Control* **11**, pg. 403-411.
- Freedman, A.N., Michalek, A.M., Marshall, J.R., Mettlin, C.J., Petrelli, N.J., Zhang, Z.F., Black, J.D., Satchidanand, S. & Asirwatham J.E. 1995. The relationship between smoking exposure and p53 overexpression in colorectal cancer. *Genetics Epidemiology* **12**, pg. 333.

- Frische, E., Baek, S.J., King, L.M., Zeldin, D.C., Eling, T.E. & Bell, D.A. 2001. Functional characterization of cyclooxygenase-2 polymorphisms. *Journal of Pharmacology and Experimental Therapeutics* **299**, pg. 468-476.
- Forgacs, I. 1988. Oncogenes and gastrointestinal cancer. *Gut* **29**, pg. 417-421.
- Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N. & Stratton, M. 2004. A CENSUS OF HUMAN CANCER GENES. *Nature Reviews* **4**, pg. 177-183.
- Garcea, G., Sharma, R.A., Dennison, A., Steward, W.P., Gescher, A. & Berry, D.P. 2003. Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention. *European Journal of Cancer* **39**, pg. 1041-1052.
- Garcia-Rodriguez, L.A. & Huerta-Alvarez, C. 2001. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. *Epidemiology* **12**, pg. 88-93.
- Gerl, R. & Vaux, D.L. 2005. Apoptosis in the development and treatment of cancer. *Carcinogenesis* **26**, pg. 263-68.
- Gertig, D.M., Stampfer, M., Haiman, C., Hennekens, C.H., Kelsey, K. & Hunter D.J. 1998. Glutathione S-Transferase GSTM1 AND GSTT1 Polymorphisms and Colorectal Cancer Risk: A Prospective Study. *Cancer Epidemiology, Biomarkers & Prevention* **7**, pg. 1001-1005.
- Giardiello, F.M., Hamilton, S.R., Krush, A.J., Piantadosi, S., Hylynd, L.M., Celano, P., Booker, S.V., Robinson, C.R. & Offerhaus, J.A. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *New England Journal of Medicine* **328**, pg. 1313-1316.

- Giet, R., McLean, D., Descamps, S., Lee, M.S., Raff, J.W., Prigent, C. & Glover, D.M. 2002. *Drosophila* Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. *Journal of Cell Biology* **156**, pg. 437-451.
- Giet, R., Petretti, C. & Prigent, C. 2005. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? *Trends in Cell Biology* **15** (5), pg. 241-250.
- Giet, R. & Prigent, C. 2000. The *Xenopus laevis* aurora/Ipl1p-related kinase pEg2 participates in the stability of the bipolar mitotic spindle. *Experimental Cell Research* **258**, 145-151.
- Giet, R. & Prigent, C. 1999. Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. *Journal of Cell Science* **112**, pg. 3591-3601.
- Giet, R., Uzbekov, R., Cubizolles, F., Le Guellec, K. & Prigent, C. 1999. The *Xenopus laevis* aurora-related protein kinase pEg2 associates with and phosphorylates the kinesin-related protein XIeg5. *Journal of Biological Chemistry* **274**, pg. 15005-15013.
- Gisselsson, D., Jonson, T., Yu, C., Martins, C., Mandahl, N., Wiegant, J., Jin, Y., Mertens, F. & Jin, C. 2002. Centrosome abnormalities, multipolar mitosis, and chromosomal instability in head and neck tumours with dysfunctional telomeres. *British Journal of Cancer* **87**, pg. 202-7.
- Glover, D.M., Leibowitz, M.H., McLean, D.A. & Parry, H. 1995. Mutations in *aurora* Prevent Centrosome Separation Leading to the Formation of Monopolar Spindles. *Cell* **81**, pg. 95-105.
- Gray, I.C., Campbell, D.A. & Spurr, N.K. 2000. Single nucleotide polymorphisms as tools in human genetics. *Human Molecular Genetics* **9** (16), pg. 2403-2408.

Greenlee, R.T., Hill-Harmon, M.B., Murray, T. & Thun, M. 2001. Cancer Statistics, 2001. *CA: A Cancer Journal for Clinicians* 51, pg. 15-36.

Greenlee R.T., Murray T., Bolden S. & Wingo P.A. 2000. Cancer statistics, 2000. *CA: A Cancer Journal for Clinicians* 50, pg. 7-33.

Gritsko, T.M., Coppola D., Paciga J.E., Lin Yang., Mei Sun., Shelley S.A., Fiorica J.V., Nicosa S.V., Cheng J.Q. 2003. Activation and Overexpression of Centrosome kinase BTAK/Aurora-A in Human Ovarian Cancer. *Clinical Cancer Research* 9, pg. 1420-1426.

Guo, S.W. & Thompson, E.A. 1992. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. *Biometrics* 48, pg. 361-372.

Hammerschmied, C.G., Stoehr, R., Walter, B., Wieland, W.F., Hartmann, A., Blaszyk, H. & Denzinger, S. 2007. Role of the *STK15* Phe311le polymorphism in renal cell carcinoma. *Oncology Reports* 17, pg. 3-7.

Hanahan, D. & Weinberg, R.A. 2000. The hallmarks of cancer. *Cell* 100, pg. 57-70.

Hannak, E., Kirkham, M., Hyman, A.A. & Oegema K. 2001. Aurora-A kinase is required for centrosome maturation in *Caenorhabditis elegans*. *Journal of Cell Biology* 155, pg. 1109-1116.

Heineman, E.F., Zahm, S.H., McLaughlin, J.K. & Vaught, J.B. 1994. Increased risk of colorectal cancer among smokers: results of a 26-year follow up of US veterans and a review. *International Journal of Cancer* 59, pg. 728-738.

Hilz, H., Wiegers, U. & Adamietz, P. 1975. Stimulation of proteinase K action by denaturing agents: Application to the isolation of nucleic acids and the

degradation of 'masked' proteins. *European Journal of Biochemistry* 56, pg. 103-108.

Hirayama, T. 1989. Association between alcohol consumption and cancer of the sigmoid colon: observation from a Japanese cohort study. *Lancet* 334, pg. 725-727.

Hirschhorn, J.N., Lohmueller, K. & Hirschhorn, K. 2002. A comprehensive review of genetic association studies. *Genetics Medicine* 4, pg. 45-61.

Hirota, T., Kunitoku, N., Sasayama, T., Marumoto, T., Zhang, D., Nitta, M., Hatakeyama, K. & Saya, H. 2003. Aurora-A and an Interacting Activator, the LIM Protein Ajuba, Are Required for Mitotic Commitment in Human Cells. *Cell* 114, pg. 585-598.

Hirvonen, A. 1999. Polymorphisms of Xenobiotic-Metabolizing Enzymes and Susceptibility to Cancer. *Environmental Health Perspective* 107(1), pg. 37-47.

Hixson, L.J., Alberts, D.S., Krutzsch, M., Einsphar, J., Brendel, K., Gross, P.H., Paranka N.S., Baier, M., Emerson S., Pamukcu, R. & Burt, R.W. 1994. Antiproliferative Effect of Nonsteroidal Antiinflammatory Drugs against Human Colon Cancer Cells. *Cancer Epidemiology, Biomarkers & Prevention* 3, pg. 433-438.

Horie, N., Aiba, H., Oguro, K., Hojo, H. & Takeishi, K. 1995. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 50-terminal regulatory region of the human gene for thymidylate synthase. *Cell Structure and Function* 20 (3), pg. 191-197.

Houlston, R.S. & Tomlinson, I.P.M. 2000. Detecting low penetrance genes in cancer: the way ahead. *Journal of Medical Genetics* 37, pg. 161-167.

- Hruban, R.H., Goggins, M., Parsons, J. & Kern, S.E. 2000. Progression model for pancreatic cancer. *Clinical Cancer Research* **6**, pg. 2969-2972.
- Hu, W. & Kavanagh, J.J. 2003. Anticancer therapy targeting the apoptotic pathway. *Lancet Oncology* **4**, pg. 721-29.
- Hunting, D. J. & Dresler, S. L. 1985. Dependence of u.v.-induced DNA excision repair on deoxyribonucleoside triphosphate concentrations in permeable human fibroblasts: a model for the inhibition of repair by hydroxyurea. *Carcinogenesis* **6**, pg. 1525-1528.
- James, S.J., Basnakian, A. G. & Miller, B. J. 1994. In vitro folate deficiency induces deoxynucleotides pool imbalance, apoptosis, and mutagenesis in Chinese hamster ovary cells. *Cancer Research* **54**, pg. 5075-5080.
- Jäne, P.A. & Meyer, R.J. 2000. Chemoprevention of Colorectal Cancer. *New England Journal of Medicine* **342** (26), pg. 1960-1968.
- Jemal, A., Thomas, A., Murray, T. & Thun, M.J. 2002. Cancer Statistics, 2002. *CA: A Cancer Journal for Clinicians* **52**, pg. 23-47.
- Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. & Thun, M.J. 2003. Cancer Statistics, 2003. *CA: A Cancer Journal for Clinicians* **53**, pg. 5-26.
- Jemal, A., Tiwari, R.C., Murray, T., Ghaffor, A., Samuels, A., Ward, E., Feuer, E.J. & Thun, M.J. 2004. Cancer Statistics, 2004. *CA: A Cancer Journal for Clinicians* **54**, pg. 8-29.
- Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J. & Thun, M.J. 2005. Cancer Statistics, 2005. *CA: A Cancer Journal for Clinicians* **55**, pg. 10-30.

- Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C. & Thun, M.J. 2006. Cancer Statistics, 2006. *CA: A Cancer Journal for Clinicians* **56**, pg. 106-130.
- Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. & Thun, M.J. 2007. Cancer Statistics, 2007. *CA: A Cancer Journal for Clinicians* **57**, pg. 43-66.
- Jeng, Y.M., Peng, S.Y., Lin, C.Y. & Hsu, H.C. 2004. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. *Journal of Clinical Cancer Research* **9**, pg. 991-997.
- Jiang, Q., Chen, K., Ma, X., Li, Q., Yu, W., Shu, G. & Yao, K. 2005. Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer. *Cancer Detection and Prevention* **29**, pg. 146-154.
- Jin, M.J., Chen, K., Song, L., Fan, C.H., Chen, Q., Zhu, Y.M., Ma, X.Y. & Yao, K.Y. 2005. The association of the DNA repair gene XRCC3 Thr241Met polymorphism with susceptibility to colorectal cancer in a Chinese population. *Cancer Genetics and Cytogenetics* **163**, pg. 38-43.
- Johannsen, L. G., Momsen, O. & Jacobsen, N. O. 1989. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. *Scandinavian Journal of Gastroenterology* **24**, pg. 799-806.
- Ju, H., Cho, H., Kim, Y.S., Kim, W.H., Ihm, C., Noh, S.M., Kim, J.B., Hahn, D.S., Choi B.Y. & Kang, C. 2006. Functional polymorphism 57Val>Ile of aurora kinase A associated with increased risk of gastric cancer progression. *Cancer Letters* **242**, pg. 273-279.
- Kaklamantis, L., Gatter, K.C., Mortensen, N. & Harris, A.L. 1992. Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. *British Journal of Cancer* **66** (4), pg. 712-716.

- Katayama, H., Brinkley, W. & Sen, S. 2003. The Aurora kinases: Role in cell transformation and tumorigenesis. *Cancer and Metastasis Reviews* 22, pg. 451-464.
- Katayama, H., Zhou, H., Li, Q., Tatsuka, M., Sen, S. 2001. Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle. *Journal of Biological Chemistry* 276, pg. 46219-46224.
- Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J. & Hayashi, S. 1993. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. *Carcinogenesis (London)* 14, pg. 1085-1089.
- Kawakami, K., Omura, K., Kanehira, E., Morishita, M. & Watanabe, Y. 1999. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. *Anticancer Research* 19, pg. 3249-3252.
- Kawakami, K. & Watanabe, G. 2003. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. *Cancer Research* 63, pg. 6004-6007.
- Keku, T., Millikan, R., Worley, K., Winkel, S., Eaton, A., Lorna, B., Martin, C & Sandler, R. 2002. 5,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphism and colon cancer in african americans and whites. *Cancer Epidemiology, Biomarkers & Prevention* 11, pg. 1611-1621.
- Kim, D.H., Ahn, Y.O., Lee, B.H., Tsuji, E., Kiyohara, C. & Kono S. 2004. Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risk of colon and rectal cancers in Korea. *Cancer Letters* 216, pg. 199-205.

- Kim, E. & Lance, P. 1997. Colorectal polyps and their relationship to cancer. *Clinical of Gastroenterology, North American, Nature* **26**, pg. 1-17.
- Kim, H.S., Newcomb, P.A., Ulrich, C.M., Keener, C.L., Bigler, J., Farin, F.M., Bostick, R.M. & Potter, J.D. 2001. Vitamin D Receptor Polymorphism and the Risk of Colorectal Adenomas: Evidence of Interaction with Dietary Vitamin D and Calcium. *Cancer Epidemiology, Biomarkers & Prevention* **10**, pg. 869-874.
- Kim, S. & Misra, A. 2007. SNP Genotyping: Technologies and Biomedical Applications. *Annual Review of Biomedical Engineering* **9**, pg. 287-320.
- Kim, J.C., Roh, S.A., Koo, K.H., Ka, I.H., Kim, H.C., Yu, C.S., Lee, K.H., Kim, J.S., Lee, H.I. & Bodmer, W.F. 2004. Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. *Familial Cancer* **3**, pg. 129-137.
- Kim, Y. I. 1999. Folate and carcinogenesis: evidence, mechanisms and implications. *Journal of Nutritional Biochemistry* **10**, pg. 66-88.
- Kim, Y.I. 2004. Folate and DNA Methylation: A Mechanistic Link between Folate Deficiency and Colorectal Cancer? *Cancer Epidemiology, Biomarkers & Prevention* **13** (4), pg. 511-519.
- Kimura, M.T., Mori, T., Conroy, J., Nowak, N.J., Satomi, S., Tamai, K. & Nagase, H. 2005. Two Functional Coding Single Nucleotide Polymorphisms in STK15 (Aurora-A) Coordinate Increase Esophageal Cancer Risk. *Cancer Research* **65** (9), pg. 3548-3554.
- Kinzler, K.W. & Vogelstein, B. 1998. Landscaping the cancer terrain. *Science* **280**, pg. 1036-1037.

- Kirsch, D.G. & Kastan, M.B. 1998. Tumor-suppressor *p53*: implications for tumor development and prognosis. *Journal of Clinical Oncology* **16**, pg. 3158-3168.
- Klatsky, A.L., Armstrong, M.A., Friedman, G.D. & Hiatt, R.A. 1988. The relations of alcoholic beverage used to colon and rectal cancer. *American Journal of Epidemiology* **128**, pg. 1007-1015.
- Knekt, P., Hakama, M., Järvinen, R., Pukkala, E. & Heliövaara, M. 1998. Smoking and risk of colorectal cancer. *British Journal of Cancer* **78**, pg. 136-139.
- Knudson, A.G. 2002. Cancer Genetics. *American Journal of Medical Genetics* **111**, pg. 96-102.
- Knudson, A.G. 1971. Mutation and cancer: statistical study of retinoblastoma. *Proceedings of the National Academy of Sciences, USA* **68**, pg. 820-823.
- Kressner, U., Inganäs, M., Byding, S., Blikstad, I., Pählin, L., Glimelius, B. & Lindmark, G. 1999. Prognostic value of *p53* genetic changes in colorectal cancer. *Journal of Clinical Oncology* **17**, pg. 593-599.
- Kotnis, A., Sarin, R. & Mulherkar, R. 2005. Genotype, phenotype and cancer: Role of low penetrance genes and environment in tumour susceptibility. *Journal of Bioscience* **30**, pg. 93-102.
- Kufer, T.A., Nigg, E.A. & Silljé, H.H.W. 2003. Regulation of Aurora-A kinase on the mitotic spindle. *Chromosoma* **112**, pg. 159-163.
- Kufer, T.A., Silljé, H.H., Korner, R., Gruss O.J., Meraldi, P. & Nigg, E.A. 2002. Human TPX2 is required for targeting Aurora-A kinase to the spindle. *Journal of Cell Biology* **158**, pg. 617-623.

Kune, G.A. & Vitetta, L. 1992. Alcohol consumption and the etiology of colorectal cancer: a review of the scientific evidence from 1957 to 1991. *Nutritional Cancer* **18**, pg. 97-111.

Kunitoku, N., Sasayama, T., Marumoto, T., Zhang, D., Honda, S., Kobayashi, O., Hatakeyana, K., Ushio, Y., Saya, H., Hirota, T. 2003. CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. *Developmental Cell* **5**, pg. 853-864.

Kwok, P.Y. & Gu, Z. 1999. Single nucleotide polymorphism libraries: why and how we building them? *Molecular Medicine Today* **5**, pg. 538-543.

Lahm, H., Schnyder, B., Wyniger, J., Borbenyi, Z., Yilmaz, A., Car, B.D., Fischer, J.R., Givel, J.C. & Ryffel. 1994. Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. *International Journal of Cancer* **59** (3). pg. 440-447.

Laken, S.J., Petersen, G.M., Gruber, S.B., Oddoux, C., Ostrer, H., Giardiello, F.M., Hamilton, S.R., Hampel, H., Markowitz, A., Klimstra, D., Jhanwar, S., Winawer, S., Offit, K., Luce, M.C., Kinzler, K.W. & Vogelstein, B. 1997. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. *Nature Genetics* **17**, pg. 79-83.

Lancaster, J.M., Wooster, R., Mangion, J., Phelan, C.M., Cochran, C., Gumbs, C., Sheila, S., Barfoot, R., Collins, N., Bignell, G., Patel, S., Hamoudi, R., Larsson, C., Wiseman, R.W., Berchuck, A., Iglehart, D., Marks, J.R., Ashworm, A., Stratton, M.R. & Futreal, A. 1996. BRCA2 mutations in primary breast and ovarian cancers. *Nature Genetics* **13**, pg. 238-240.

Landi, S., Bottari, F., Gemignani, F., Gioia-Patricola, L., Guino, E., Osorio A., Javier de Oca, Capella, G., Canzani, F. & Moreno, V. 2007. Interleukin-4 and interleukin-4

receptor polymorphisms and colorectal cancer risk. *European Journal of Cancer* 43, pg. 762-768.

Lane, D.P. 1992. Cancer. p53, guardian of the genome. *Nature* 358, pg. 15-16.

La Vecchia, C., Negri, E., Franceschi, S., Conti, E., Montella, M., Giacosa, A., Falcini, A. & Decarli, A. 1997. Aspirin and colorectal cancer. *British Journal of Cancer* 76, pg. 675-677.

Lengauer, C., Kinzler, K.W. & Vogelstein, B. 1998. Genetic instabilities in human cancers. *Nature* 396, pg. 643-649.

Le Marchand, L., Wilkens, L.R., Kolonel, L.N., Hankin, J.H. & Lyu, L.C. 1997. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. *Cancer Research* 57, pg. 4787-4794.

Lim, G.C.C., Halimah Yahya & Lim, T.O. 2002. The First Report of the National Cancer Registry, Cancer Incidence in Malaysia. *National Cancer Registry; The Ministry of Health, Malaysia* pg. 1-192.

Li, D., Zhu, J., Firozi, P.F., Abbruzzese, J.L., Evans, D.B., Cleary, K., Friess, H. & Sen, S. 2003. Overexpression of Oncogenic STK15/BTAK/Aurora-A Kinase in Human Pancreatic Cancer. *Clinical Cancer Research* 9, pg. 991-997.

Lin, H.J., Lakkides, K.M., Keku, T.O., Reddy, S.T., Louie, A.D., Kau, I.H., Zhou, H., Jason Gim, S.Y., Ma, H.L., Matthies, C.F., Dai, A., Huang, H.F., Materi, A.M., Jesse Lin, H., Frankl, H.D., Lee E.R., Hardy, S.I., Herschman, H.R., Henderson, B.E., Kolonel, L.N., Marchand, L.L., Garavito, M., Sandler, R.S., Haile, R.W. & Smith, W.L. 2002. Prostaglandin H Syntase 2 Variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. *Cancer Epidemiology, Biomarkers & Prevention* 11, pg. 1305-1315.

- Littlepage, L.E., Wu, H., Andresson, T., Deanehan, J.K., Amundadottir, L.T., Ruderman, J.V. 2002. Identification of phosphorylated residues that affect the activity of the mitotic kinase aurora-A. *Proceedings of the National Academy of Science, USA* **99**, pg. 15440-15445.
- Locker, G.Y., Kaul, K., Weinberg, D.S., Gatalica, Z., Gong, G., Peterman, A., Lynch, J., Klatzco, L., Olopade, O.I., Bomzer, C.A., Newlin, A., Keenan, E., Tajuddin, M., Knezetic, J., Coronel, S. & Lynch, H.T. 2006. The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. *Cancer Genetics and Cytogenetics* **169**, pg. 33-38.
- Logan, R.F., Little, J., Hawtin, P.G. & Hardcastle, J.D. 1993. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. *British Medical Journal* **307**, pg. 285-289.
- Lointier, P., Wagovich, M.J., Saez, S., Levin, B., Widrick, D.M. & Boman, B.M. 1987. The role of vitamin D3 in the proliferation of human colon cancer cell lines in vitro. *Anticancer Research* **7**, pg. 817-822.
- Loktionov, A., Watson, M.A., Stebbings, W.S.L., Speakman C.T.M. & Bingham S.A. 2003. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. *Cancer Letters* **189**, pg. 189-196.
- Makos, M., Nelkin, B.D., Lerman, M.I., Latif, F.Z. & Baylin, S.B. 1992. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. *Proceedings of the National Academy of Sciences, USA* **89**, pg. 1929-1933.

- Marahatta, S.B., Punyarit, P., Bhudisawasdi, V., Paupairoj, A., Wongkham, S. & Petmitr, S. 2006. Polymorphism of glutathione S-transferase Omega gene and risk of cancer. *Cancer Letters* 236, pg. 276-281.
- Marie, H., Pratt, S.J., Betson, M., Epple, H., Kittler, J.T., Meek, L., Moss, S.J., Troyanovsky, S., Attwell, D., Longmore, G.D. & Braga, V.M.M. 2003. The LIM Protein Ajuba Is Recruited to Cadherin-dependent Cell Junctions through an Association with  $\alpha$ -Catenin. *The Journal of Biological Chemistry* 276 (2), pg. 1220-1228.
- Marnett, L.J. & DuBois, R.N. 2002. COX-2: A Target for Colon Cancer Prevention. *Annual Review of Pharmacology and Toxicology* 42, pg. 55-80.
- Marsh, S., Kowk, P.Y. & McLeod, H.L. 2002. SNP Database and Pharmacogenetics: Great Start, but a Long Way to Go. *Human Mutation* 20, pg. 174-179.
- Marumoto, T., Toru H., Tetsuro M., Naoko K., Zhang D., Yasuko I., Takashi S., Shinji K., Tatsuyuki M., Norihiko T., Masashi K., Okano Y. & Saya H. 2002. Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. *Genes to Cell* 7, pg. 1173-1181.
- Marumoto, T., Zhang, D. & Saya, H. 2005. Aurora A—A Guardian of Poles. *Nature Reviews* 5, pg. 42-50.
- Marumoto, T., Honda, S., Hara, T., Nitta, M., Hirota, T., Kohmura, E. & Saya, H. 2003. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. *Journal of Biological Chemistry* 278, pg. 51786-51795.
- Meraldi, P., Honda, R. & Nigg, E.A. 2004. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. *Current Opinion in Genetics and Development* 14, pg. 29-36.

- Meuth, M. 1981. Role of deoxynucleotides triphosphate pools in the cytotoxic and mutagenic effects of DNA alkylating agents. *Somatic Cell Genetics* 7, pg. 89-102.
- Miao, X., Sun, T., Wang, Y., Zhang, X., Tan, W. & Lin, D. Functional STK15 Phe31Ile Polymorphism Is Associated with the Occurrence and Advanced Disease Status of Esophageal Squamous Cell Carcinoma. *Cancer Research* 64, pg. 2680-2683.
- Miki, Y., Katagiri, T., Kasumi, F., Yoshimoto, T. & Nakamura, Y. 1996. Mutation analysis in the BRCA2 gene in primary breast cancers. *Nature Genetics* 13, pg. 245-247.
- Milam, M.R., Gu, J., Yang, H., Celestino, J., Wu, W., Horwitz, I.B., Lacour, R.A., Westin, S.N., Gershenson, D.M., Wu, X. & Lu, K.H. 2007. STK15 F31I polymorphism is associated with increased uterine cancer risk: A pilot study. *Gynecologic Oncology* doi: 10.1016/j.ygyno.2007.05.025.
- Minamoto, T., Yamashita, N., Ochiai, A., Mai, M., Sugimura, T., Ronai, Z. & Esumi, H. 1995. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. *Cancer* 75, pg. 1520-1526.
- Mitrunen, K. & Hirvonen, A. 2003. Molecular epidemiology of sporadic breast cancer the role of polymorphic genes involved in oestrogen biosynthesis and metabolism. *Mutation Research* 544, pg. 9-41.
- Morganti, M., Ciantelli, M., Giglioni, B., Putignano, A.L., Nobili, S., Papi, L., Landini, I., Napoli, C., Valanzano, R., Cianchi, F., Boddi, V., Tonelli, F., Cortesini, C., Mazzei, T., Genuardi, M. & Mini, E. 2005. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. *European Journal of Cancer* 41, pg. 2176-2183.

- Motembault, E. & Prigent, C. 2005. Aurora kinases; therapeutic potential. *Drugs of the Future* 30, pg. 1-9.
- Müller, H. Hj, Heinemann, K. & Dobbie, Z. 2000. Genetics of hereditary colon cancer—a basis for prevention? *European Journal of Cancer* 36, pg. 1215-1223.
- Munemisu, S., Albert, I., Souza B., Rubinfield, B. & Polakis, P. 1995. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. *Proceedings of the National Academy of Sciences, USA* 92, pg. 3046-3050.
- Muscat, J.E., Stellman, S.D. & Wynder, E.L. 1994. Nonsteroidal antiinflammatory drugs and colorectal cancer. *Cancer* 74, pg. 1847-1854.
- Nagasubramaniam, R., Innocenti, F. & Ratain, M.J. 2003. Pharmacogenetics in Cancer Treatment. *Annual Review of Medicine* 54, pg. 437-452.
- Newcomb, P.A., Storer, B.E. & Marcus, P.M. 1995. Cigarette smoking in relation to risk of large bowel cancer in women. *Cancer Research* 55, pg. 4906-4909.
- Nordlund, L.A., Cartensen, J.M. & Pershagen, G. 1997. Cancer incidence in female smokers: a 26-year follow-up. *International Journal of Cancer* 73, pg. 625-628.
- Nyrén, O., Bergström, R., Nyström, L., Engholm, G., Ekbom, A., Adami, H.O., Knutsson, A. & Stjernberg, N. 1996. Smoking and colorectal cancer: a 20-year follow-up study of Swedish construction workers. *Journal of National Cancer Institute* 88, pg. 1302-1307.
- Osian, G., Procopciuc, L. & Vlad, L. 2006. NAT2 Gene Polymorphism and Sporadic Colorectal Cancer: Prevalence, Tumor Stage and Prognosis. A Preliminary Study in 70 Patients. *Journal of Gastroenterology and Liver Disease* 15 (4), pg. 347-353.

- Palazzo, R.E., Vogel, J.M., Schnackenberg, B.J., Hull, D.R. & Wu, X. 2000. Centrosome maturation. *Current Topics in Developmental Biology* 49, pg. 449-470.
- Park, K.S., Woo, M., Nam, J.H. & Kim, J.C. 2006. Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. *Cancer Letters* 237, pg. 199-206.
- Parkin, D. 1998. Epidemiology of cancer: global patterns and trends. *Toxicology Letter* 102-103, pg. 227-234.
- Parkin, D., Pisani, P. & Ferlay, J. 1999. *Global cancer statistics. CA: A Cancer Journal for Clinicians* 49, pg. 33-64.
- Peleg, I.I., Lubin, M.F., Cotsonis, G.A., Clark, W.S. & Wilcox, C.M. 1996. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. *Digestive Diseases and Sciences* 41, pg. 1319-1326.
- Pence, B.C. 1993. Role of calcium in colon cancer prevention: experimental and clinical studies. *Mutation Research* 290, pg. 87-95.
- Pence, B.C., Dunn, D.M., Zhao, C., Patel, V., Hunter, S. & Landers, M. 1996. Protective effects of calcium from nonfat dried milk against colon carcinogenesis in rats. *Nutritional Cancer* 25, pg. 35-45.
- Peto, J. & Houlston, R.S. 2001. Genetics and the common cancers. *European Journal of Cancer* 37, pg. S88-S96.
- Pfost, D.R., Boyce-Jacino, M.T. & Grant, D.M. 2000. A SNPshot: pharmacogenetics and the future of drug therapy. *Trends in Biotechnology* 18, pg. 334-338.

- Pierce, A.M., Schneider-Broussard, R., Philhower, J.L. & Johnson, D.G. 1998. Differential activities of E2F family members: Unique functions in regulating transcription. *Molecular Carcinogenesis*. **22** (3), pg. 190-198.
- Pihan, G.A., Purohit, A., Wallace J., Malhotra, R., Liotta, L. & Doxsey S.J. 2001. Centrosome Defects Can Account for Cellular and Genetic Changes That Characterize Prostate Cancer Progression. *Cancer Research* **61**, pg. 2212-2219.
- Pirmohamed, M. & Park, B.K. 2001. Genetic susceptibility to adverse drug reactions. *Trends in Pharmacological Science* **22**(6), pg. 298-305.
- Prior, T.W., Chadwick, R.B., Papp, A.C., Arcot, A.N., Isa, A.M., Pearl, D.K., Stermmermann, G., Peresepe, A., Loukola, A., Aaltonen, L.A. & Albert De La Chapelle. 1999. The I1307K Polymorphism of the APC Gene in Colorectal Cancer. *Gastroenterology* **116**, pg. 58-63.
- Potter, J. 1997. Cancer, nutrition and food: Colon, rectum. *Food, Nutrition and Prevention of Cancer, American Institute for Cancer Research*, pg. 216-251.
- Pullarkat, S.T., Stoehlmacher, J., Ghaderi, V., Xiong, Y.P., Ingles, S.A., Sherrod, A., Warren, R., Wei, D.T., Groshen, S. & Lenz, H.J. 2001. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. *The Pharmacogenomics Journal* **1** (1), pg. 65-70.
- Rashid, A., Houlihan, P.S., Booker, S., Peterson, S.M., Giardiello, F.M. & Hamilton, S.R. 2000. Phenotypic and molecular characteristic of hyperplastic polyposis. *Gastroenterology* **119**, pg. 323-332.
- Rhodes, J.M. & Campbell, B.J. 2002. Inflammation and colorectal cancer: IBD associated and sporadic cancer compared. *Trends in Molecular Medicine* **8**, pg. 10-15.

- Ries, L., Wingo, P., Miller, D., Howe, H.L., Weir, H.K., Rosenberg, H.M., Vernon, S.W., Cronin, K. & Edwards, B.K. 2000. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. *Cancer* **88**, pg. 2398-2424.
- Robinette C., Hrubec Z. & Fraumeni J.F Jr. 1979. Chronic alcoholism and subsequent mortality in World War II veterans. *American Journal of Epidemiology* **109**, pg. 687-700.
- Rose, M.G., Farrell, M.P. & Schmitz, J.C. 2002. Thymidylate synthase: a critical target for cancer chemotherapy. *Clinical Colorectal Cancer* **1**, pg. 220-229.
- Rubinfeld, B., Souza, B., Albert, I., Munemitsu, S. & Polakis, P. 1995. The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin. *Journal of Biological Chemistry* **270** (10), pg. 5549-5555.
- Salaspuro, M.P. 2003. Alcohol consumption and cancer of the gastrointestinal tract. *Best Practice and Research Clinical Gastroenterology* **17**, pg. 679-694.
- Sambrook, J. & Russell, D.W. 2001. *Molecular Cloning, 3<sup>rd</sup> Edition, Volume 1*. Cold Spring Harbor Press, Cold Spring Harbor, New York, USA.
- Samowitz, W.S., Wolff, R.K., Ma, K.N., Andersen, K., Caan, B. & Slaterry, M.L. 2006. Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. *Mutation Research* **595**, pg. 117-124.
- Sandler, R. 1996. Epidemiology and risk factors for colorectal cancer. *Clinical of Gastroenterology North America* **25**, pg. 717-735.

- Sansbury, L.B., Millikan, R.C., Schroeder, J.C., North, K.E., Moorman, P.G., Keku, T.O., Rene' de Cotret, A., Player, J. & Sandler, R.S. 2006. COX-2 Polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). *Cancer Causes and Control* 17, pg. 257-266.
- Santi, D.V., McHenry, C.S. & Sommer, H. 1974. Mechanism of interaction of thymidylate synthase with 5-fluorodeoxyuridylate. *Biochemistry* 13, pg. 471-481.
- Sato, N., Mizumoto, K., Nakamura, M., Nakamura, K., Kusumoto, M., Niiyama, H., Ogawa, T. & Tanaka, M. 1999. Centrosome Abnormalities in Pancreatic Ductal Carcinoma. *Clinical Cancer Research* 5, pg. 963-970.
- Scheppach, W., Bingham, S., Boutron-Ruault, M-C., Gerhardsson de Verdier M., Moreno V., Nagengast, F.M., Reifen, R., Riboli, E., Seitz, H.K. & Wahrendorf, J. 1999. WHO Consensus statement on the role of nutrition in colorectal cancer. *European Journal of Cancer Prevention* 8, pg. 57-62.
- Schmidt, W. & Popham, R. 1981. The role of drinking and smoking in mortality from cancer and the other causes in male alcoholics. *Cancer* 47, pg. 1031-1041.
- Sen, S. 2000. Aneuploidy and cancer. *Current Opinion in Oncology* 12, pg. 82-88.
- Sheathing, M., Buras, R.R., Devoid, F., Schumaker, L.M., Nafta, R.J., Uskokovic, M.R., Brenner, R.V. & Evans, S.R.T. 1994. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. *Cancer Research* 54, pg. 407-464.
- Sheer, C.J. 1996. Cancer cell cycles. *Sciences* 274, pg. 1672-1677.

- Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigelski, E.M. & Sirotnik, K. 2000. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Research* **29** (1), pg. 308-311.
- Shibata, J., Aiba, K., Shibata, H., Minowa, S. & Horikoshi, N. 1998. Detection and quantitation of thymidylate synthase mRNA in human colon adenocarcinoma cell line resistant to 5-fluorouracil by competitive PCR. *Anticancer Research* **18** (3a), pg. 1457-1463.
- Shimuzu, M., Mack, T., Ross, R. & Henderson, B.E. 1987. Cancer of the gastrointestinal tract among Japanese and white immigrants in Los Angeles County. *Journal of the National Cancer Institute* **78**, pg. 223-228.
- Shindo, M., Nakano, H., Kuroyanagi, H., Shirasawa, T., Mihara, M., Gilbert, D.J., Jenkins, N.A., Copeland, N.G., Yagita, H. & Okumura, K. 1998. cDNA cloning, expression, subcellular localization and chromosomal assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 and 2. *Biochemical and Biophysical Research Communication* **244** (1), pg. 285-292.
- Singer, I.I., Kawa, D.W., Schloemann, S., Tessner, T., Riehl, T. & Stenson, W.F. 1998. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. *Gastroenterology* **115**, pg. 297-306.
- Sjalander, A., Birgander, R., Athlin, L., Stenling, R., Rutegard, J., Beckham, L. & Beckham, G. 1995. P53 germ line haplotypes associated with increased risk for colorectal cancer. *Carcinogenesis (London)* **16**, pg. 1461-1464.
- Slattery, M.L., Curtin, K., Anderson, K., Ma, K.N., Ballard, L., Edwards, S., Schaffer, D., Potter, J., Leppert, M. & Samowitz, W.S. 2000. Associations between cigarette

- smoking, lifestyle factors, and microsatellite instability in colon tumors. *Journal of the National Cancer Institute* 92, pg. 1831-1836.
- Slattery, M.L., West, D.W., Robinson, L.M., French, T.K., Ford, M.H., Schuman, K.L. & Sorenson, A.W. 1990. Tobacco, alcohol, coffee, and caffeine as risk factors for colon cancer in a low-risk population. *Epidemiology* 1, pg. 141-145.
- Smalley, W., Ray, W.A., Daugherty, J. & Griffen, M.R. 1999. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. *Archives of Internal Medicine*. 159, pg. 161-166.
- Smigelski, E.M., Sirotnik, K., Ward, M. & Sherry, S.T. 2000. dbSNP: a database of single nucleotide polymorphism. *Nucleic Acids Research* 28 (1), pg. 352-355.
- Smith, A., Stern, H., Penner, M., Stern, H.S., Penner, M., Kazy, H., Mitri, A., Bapat, B.V., Gallinger, S. 1994. Somatic *APC* and *K-ras* codon 12 mutations in aberrant crypt foci from human colons. *Cancer Research* 54, pg. 5527-5530.
- Stemmermann, G.N., Nomura, A.M.Y., Chyou, P.H., Yoshizawa, C. 1990. Prospective study of alcohol intake and large bowel cancer. *Digestive Diseases and Sciences* 35, pg. 1414-1420.
- Stryker, S. J., Wolff, B. G., Culp, C. E., Libbe, S. D., Ilstrup, D. M. & MacCarty, R.L. 1987. Natural history of untreated colonic polyps. *Gastroenterology* 93, pg. 1009-1013.
- Sun, T., Miao, X., Wang, J., Tan, W., Zhou, Y., Yu, C. & Lin, D. 2004. Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. *Carcinogenesis* 25 (11), pg. 2225-2230.

- Sutherland, G. R. 1988. The role of nucleotides in human fragile site expression. *Mutation Research* 200, pg. 207-213.
- Su, L.K., Vogelstein, B. & Kinzler, K.W. 1993. Association of the *APC* tumor suppressor protein with catenins. *Science* 262, pg. 1734-1737.
- Suh, O., Mettlin, C. & Petrelli, N.J. 1993. Aspirin use, cancer, and polyps of the large bowel. *Cancer* 72, pg. 1171-1177.
- Tanaka, T., Kimura, M., Matsunaga, K., Fukada, D., Mori, H. & Okano, Y. 1999. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. *Cancer Research* 59, pg. 2041-2044.
- Tanner, M.M., Grenman, S., Koul, A., Johannsson, O., Meltzer, P., Pejovic, T., Borg, A. & Isola, J.J. 2000. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. *Clinical Cancer Research* 6, pg. 1833-1839.
- Tatsuka, M., Katayama, H., Ota, T., Tanaka, T., Odashima, S., Suzuki, F. & Terada, Y. 1998. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. *Cancer Research* 58, pg. 4811-4816.
- Tetsu, O. & McCormick, F. 1997. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature* 398, pg. 422-426.
- Thompson, L.H. & West, M.G. 2002. XRCC1 keeps DNA from getting stranded. *Mutation Research* 459, pg. 1-18.
- Toi, M., Bicknell, R. & Harris, A.L. 1992. Inhibition of colon and breast carcinoma cell growth by interleukin-4. *Cancer Research* 52 (2), pg. 275-279.

- Torring, N., Bihl, K. & Orntoft, T. 2003. Screening for single nucleotide polymorphism (snp) in association with sporadic colorectal cancer. *299 POSTER SESSION*, pg. 91-92.
- Tortola, S., Marcuello, E., González, I., Reyes, G., Arribas, R., Aiza, G., Sancho, F.J., Peinado, M.A. & Capella, G. 1999. *p53* and *K-ras* gene mutation correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. *Journal of Clinical Oncology* 17, pg. 1375-1381.
- Tsai, M.Y., Wiese, C., Cao, K., Martin, O., Donovan, P., Ruderman, J., Prigent, C., Zheng, Y. 2003. A Ran signaling pathway mediated by the mitotic kinase Aurora A in spindle assembly. *Nature Cell Biology* 5, pg. 242-248.
- Tsai, M.Y. & Zheng, Y. 2005. Aurora A Kinase-Coated Beads Function as Microtubule-Organizing Centers and Enhance RanGTP-Induced Spindle Assembly. *Current Biology* 15, pg. 2156-2163.
- Turini, M.E. & DuBois, R.N. 2002. Cyclooxygenase-2: A Therapeutic Target. *Annual Review of Medicine* 53, pg. 35-57.
- Uchiyama, A., Essner, R., Doi, F., Nguyen, T., Ramming, K.P., Nakamura, T., Morton, D.L. & Hoon, D.S.B. 1996. Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas. *Journal of Cellular Biochemistry* 62 (4), pg. 443-453.
- Ulrich, C.M., Robien, K. & McLeod, L. 2003. Cancer Pharmacogenetics: Polymorphisms, Pathways and Beyond. *Nature Review of Cancer* 3, pg. 912-920.
- van der Hel, O.L., Peeters, P.H., Hein, D.W., Doll, M.A., Grobbee, D.E., Kromhout, D. & Bueno de Mesquita, H.B. 2003. NAT2 slow acetylation and GSTM1 null

genotypes may increase postmenopausal breast cancer risk in long term smoking women. *Pharmacogenetics* 13, pg. 399-407.

Vane, J.R., Bakhle, Y.S. & Botting, R.M. 1998. CYCLOOXYGENASES 1 AND 2. *Annual Review of Pharmacology and Toxicology* 38, pg. 97-120.

Vatn, M.H. & Stalsberg, H. 1982. The prevalence of polyps of the large intestine in Oslo: an autopsy study. *Cancer* 49, pg. 819-825.

Vinas, S.J., Biendicho, P.P., Pinol, F.C., Miguelanz, G.S. & Perez, H.S. 1998. Calcium inhibits colon carcinogenesis in an experimental model in the rat. *European Journal of Cancer* 34, pg. 1941-1945.

Vogelstein, B., Fearon, E. R. & Hamilton, S. R. 1988. Genetic alterations during colorectal-tumour development. *New England Journal of Medicine* 319, pg. 525-532.

Walter, A.O., Seghezzi, W., Korver, W., Sheung, J. & Lees, E. 2000. The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. *Oncogene* 19, pg. 4906-4916.

Warrell, D.A., Cox, T.M., Firth, J.D. & Benz, E.J. 2003. *Oxford Textbook of Medicine*, vol. 2. Oxford University Press, pg. 483-486.

Weinberg, R.A. 1994. Oncogenes and tumor suppressor genes. *CA: A Cancer Journal for Clinicians* 44, pg. 160-170.

Weinshilboum, R.M. & Wang L. 2006. Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. *Annual Review of Genomics and Human Genetics* 7, pg. 223-245.

- Weiss, R.A. 1982. *RNA Tumour Viruses*. Cold Spring Harbor, USA.
- Welfare, M., Adeokun, M., Bassendine, M.F. & Daly, A.K. 1999. Polymorphisms in GSTP1, GSTM1, and GSTT1 and Susceptibility to Colorectal Cancer. *Cancer Epidemiology, Biomarkers & Prevention* 8, pg. 289-292.
- Whittmann, T., Wilm, M., Karsenti, E. & Vernos, I. 2000. TPX2, a novel *xenopus* MAP involved in spindle pole organization. *Journal of Cell Biology* 149 (7), pg. 1405-1418.
- Wickramasinghe, S.N. & Fida, S. 1984. Bone marrow cells from vitamin B12- and folate-deficient patients misincorporate uracil into DNA. *Blood* 83, pg. 1656-1661.
- Wieggers, U. & Hilz, H. 1971. A new method using "proteinase K" to prevent mRNA degradation during isolation from HeLa cells. *Biochemical and Biophysical Research Communication* 44, pg. 513-519.
- Williams, A. R., Balasooriya, B. A. & Day, D. W. 1982. Polyps and cancer of the large bowel: a necropsy study in Liverpool. *GUT* 23, pg. 835-842.
- Wisotzkey, J.D., Toman, J., Bell, T., Monk, J.S. & Jones, D. 1999. MTHFR (C677T) Polymorphisms and Stage III Colon Cancer: Response to Therapy. *Molecular Diagnosis* 4(2), pg. 95-99.
- Wogan, G.N., Hecht, S.S., Felton, J.S., Conney, A.H. & Loeb, L.A. 2004. Environmental and chemical carcinogenesis. *Seminars of Cancer Biology* 14, pg 473-486.
- World Cancer Research Fund (WCRF) Panel. 1997. *Food, Nutrition and the Prevention of Cancer: A Global Perspective*. American Institute for Cancer Research, Washington DC.

- Yamada, K., Araki, S., Tamura, M., Sakai, I., Takahashi, Y., Kashihara, H. & Kono S. 1997. Case-control study of colorectal carcinoma in situ and cancer in relation to cigarette smoking and alcohol use (Japan). *Cancer Causes Control* **8**, pg. 780-785.
- Yew, P.R. & Berk, A.J. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. *Nature* **357**, pg. 82-85.
- Zhang, W.J., Miao, X., Tong, S., Zhang, X., Qu, S., Tan, W., Xiong, P., Zheng, R., Lin, D. 2004. Association between genetic polymorphism in STK15 and risk of colorectal cancer in a Chinese population. *Chinese Journal of Oncology*, pg. 43-46.
- Zhao, C., Xu, G., Shi, X., Ma, J., Zhang, Y., Sheen, L. & Yang, Q. 2005. Simultaneous genotyping of multiple single nucleotide polymorphisms of K-ras gene with a home-made kit. *Journal of Chromatography B* **795**, pg. 55-60.
- Zhou, H., Jian, K., Ling Z., Kuo W.L., Gray J.W., Sahin A., Brinkley B.R. & Subrata Sen. 1998. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. *Nature Genetics* **20**, pg. 189-93.